Genome Profiling (GP)

 

            Molecular genotype-based characterization of isolates (differing in sequence even with a single-base) within a species is a vital essence for classification of Life in present information-rich age of transparent Biology. The most common technology must be the ribosomal-DNA sequencing but is not sufficient nor suitable for identification of species. For such purposes, our laboratory have invented a realistic solution for genome identification and termed as Genome Profiling (GP) which uses TGGE (Temperature Gradient Gel Electrophoresis) analysis of random-PCR products (J. Biochemistry, 2000). We have refined GP to quantitatively measure the closeness between two unidentified genomes and further improved by introducing its miniaturized-version, giving a 100-fold high-throughput productivity by drastically reducing the time, operation effort and cost of the system (Electrophoresis, 2000). A development and successful operation of web-based databases for GP (Genome Biol., 2002) makes this technique further distinct from known molecular techniques. GP is currently considered to have the most optimal nature for identification of species since it can reproducibly reduce a huge amount of genome information to a manageable size and can extract a sufficient amount of required information. In terms of the reduction of labor time (<4h), relatively low running cost (<$3 per sample), parallel and easy application, and reliable results, GP can be considered a powerful, potential tool for the routine identification of species. Here we believe, GP will lead to a revolutionary improvement in species authentications studies and must be beneficial in many fields of biology, including agricultural or microbe-related disciplines and particularly, in clinical microbiology in developing countries, land of rich-of-clinical isolates but limited in resources.

  

 

 We are interested to use the GP in following research proposals:

*       Rapid detection, identification, genetic characterization and forensic attribution of high-priority clinical strains including viruses (e.g, Influenza-A), bacteria (e.g. Salmonella) or yeast (e.g. Candida) pathogens.

*       Identification and evaluation of genetic diversity in inter- and intra-species of medicinal plants (e.g, Withania somnifera, Plumbago zeylanica).

*       Introduction of multi-micro TGGE for high-throughput genome analysis.